Aldo-Keto Reductase 1C3 Mediates Chemotherapy Resistance in Esophageal Adenocarcinoma via ROS Detoxification
Authors:
- Chenghui ZhouCZChenghui Zhou
- Zhefang WangZWZhefang Wang
- Jiahui LiJLJiahui Li
- Xiaolin WuXWXiaolin Wu
- Ningbo FanNFNingbo Fan
- Dai LiDLDai Li
- Fanyu LiuFLFanyu Liu
- Patrick S. PlumPPPatrick S. Plum
- Sascha HoppeSHSascha Hoppe
- Axel M. HillmerAHAxel M. Hillmer
- Alexandar QuaasAQAlexandar Quaas
- Florian GebauerFGFlorian Gebauer
Open Access
Abstract
Esophageal adenocarcinoma (EAC) is one of the most lethal malignancies, and limits promising treatments. AKR1C3 represents a therapeutic target to combat the resistance in many cancers. However, the molecular mechanism of AKR1C3 in the chemotherapy resistance of EAC is still unclear. We found that the mRNA level of AKR1C3 was higher in EAC tumor tissues, and that high AKR1C3 expression might be associated with poor overall survival of EAC patients. AKR1C3 overexpression decreased cell death induced by chemotherapeutics, while knockdown of AKR1C3 attenuated the effect. Furthermore, we found AKR1C3 was inversely correlated with ROS production. Antioxidant NAC rescued chemotherapy-induced apoptosis in AKR1C3 knockdown cells, while the GSH biosynthesis inhibitor BSO reversed a protective effect of AKR1C3 against chemotherapy. AKT phosphorylation was regulated by AKR1C3 and might be responsible for eliminating over-produced ROS in EAC cells. Intracellular GSH levels were modulated by AKR1C3 and the inhibition of AKT could reduce GSH level in EAC cells. Here, we reported for the first time that AKR1C3 renders chemotherapy resistance through controlling ROS levels via AKT signaling in EAC cells. Targeting AKR1C3 may represent a novel strategy to sensitize EAC cells to conventional chemotherapy.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BR1614.11-1)
- Köln Fortune Program/Faculty of Medicine, University of Cologne (417-2018)
This publication has 62 references indexed in Scilit:
- Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic FunctionsPLOS ONE, 2013
- Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and TherapyAntioxidants & Redox Signaling, 2012
- Oxidative Stress and Antioxidant DefenseWorld Allergy Organization Journal, 2012
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nature Reviews Drug Discovery, 2009
- Regulation of glutathione synthesisMolecular Aspects of Medicine, 2009
- Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear functionInternational Journal of Cancer, 2007
- Role of Insulin-Induced Reactive Oxygen Species in the Insulin Signaling PathwayAntioxidants & Redox Signaling, 2005
- Insulin Signaling Regulates γ-Glutamylcysteine Ligase Catalytic Subunit Expression in Primary Cultured Rat HepatocytesThe Journal of Pharmacology and Experimental Therapeutics, 2004
- PI3K/Akt and apoptosis: size mattersOncogene, 2003
- The Hallmarks of CancerCell, 2000